Logo

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Share this

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Shots:

  • Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
  • The US FDA granted PR to the therapy- allowing the agency to take action on NDA within 6mos. of acceptance compared to 10mos. under standard review
  • Finerenone is an investigational- non-steroidal- selective MRA and has showed a reduction in harmful effects of MR overactivation. The therapy has demonstrated positive kidney and CV outcomes in patients with CKD and T2D

 ­ Ref: BusinessWire | Image: Bayer

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions